Pipeline

April 23, 2018

Company	Drug/Device	Medical Condition	Status
Pfizer, Inc.	PF-06939926	Duchenne muscular dystrophy (DMD)	Phase Ib trial initiated
Synlogic	SYNB1618	Phenylketonuria (PKU)	Phase I/IIa trial initiated
NovoCure Ltd.	STELLAR	mesothelioma	Phase II top-line results announced evaluating 80 subjects
Fervent Pharmaceuticals	FP-101	vasomotor symptoms	Phase IIa trials initiated enrolling 112 subjects from across the southeastern U.S.
Janssen Pharmaceutical Companies of Johnson & Johnson	esketamine	major depressive disorder at imminent risk for suicide	Phase IIa results announced evaluating 68 subjects
Glenmark Pharmaceuticals	GBR 830	moderate-to-severe atopic dermatitis	Phase IIb trials initiated enrolling 392 subjects
Amgen	Aimovig (erenumab)	migraine	Phase IIIb final results announced evaluating 246 subjects
Genentech, Inc.	HEMLIBRA (emicizumab-kxwh)	hemophilia A without factor VIII	Breakthrough Therapy Designation granted by the FDA
King-Devick technologies, inc.	K-D Balance	conditions that could affect balance	510(k) clearance granted by the FDA
Alkermes	ALKS 54641	major depressive disorder	NDA filed with the FDA
NeuroVive Pharmaceutical AB	KL1333	inherited mitochondrial respiratory chain diseases (MRCD)	Orphan Drug Designation granted by the FDA
Boehringer Ingelheim Pharmaceuticals, Inc.	Praxbind (idarucizumab)	patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding	FDA approved